NEW YORK (GenomeWeb) – Cancer Genetics reported today that its third quarter revenues were up 68 percent year over year.

The oncology-focused clinical services firm reported total Q3 revenues of $6.8 million compared to $4 million in Q3 2015. 

The firm reported a 204 percent increase in clinical services test volume to 7,334 tests, driven by an increase in immuno-oncology testing, companion diagnostic testing for PD-L1, and solid tumor profiling.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.